A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future Publisher Pubmed



Gholamzad M¹ ; Ebtekar M² ; Ardestani MS³ ; Azimi M⁴ ; Mahmodi Z¹ ; Mousavi MJ^{4, 5, 6} ; Aslani S^{4, 6} Show Affiliations
Source: Inflammation Research Published:2019

Abstract

Background: Multiple sclerosis (MS) is a chronic and autoimmune disease of the central nervous system (CNS), mainly characterized by inflammatory demyelination, which manifests as relapses and diffuse damage and brain volume loss, both accounting for neurodegeneration, and therefore, physical disability. MS typically affects young adults and is commonly diagnosed in the early years by acute relapses, which then followed through partial or complete remission period. The clinical course of MS is characterized as four major classifications, including relapsing–remitting (RRMS), primary progressive (PPMS), progressive relapsing (PRMS), and secondary progressive (SPMS). Purpose: This review provides comprehensive overview of the current treatments and future innovative approaches in the treatment of MS. Results: Currently, there is no definite cure for MS. The treatment of MS has mainly been based on the prescription of immunosuppressive and immune-modulating agents. However, a number of disease-modifying treatments (DMTs) have been designed that reduce the attack rate and delay progression and mainly target inflammation settings in these patients. Although remarkable advancements have occurred in the therapy of MS, the rate of progressive disability and early mortality is still worrisome. Recently, a monoclonal antibody (ocrelizumab) was demonstrated to be beneficial in a clinical trial of primary progressive MS. Furthermore, novel treatment strategies concentrating on the remyelination or neuroprotection are under evaluation. Conclusions: In spite of prosperous experiences in MS therapy, the future research, hopefully, will bring substantial improvements in the understanding and approaches of MS therapy. © 2018, Springer Nature Switzerland AG.